Related references
Note: Only part of the references are listed.The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
E. Terpos et al.
LEUKEMIA (2008)
Myeloma bone-disease and proteasome inhibition therapies
Evangelos Terpos et al.
BLOOD (2007)
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
Nicola Giuliani et al.
BLOOD (2007)
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
Evangelos Terpos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Myeloma bone disease: pathophysiology and management
E Terpos et al.
ANNALS OF ONCOLOGY (2005)
Share Paper
